5-アミノレヴリン酸に関連した持続性低血圧の危険因子:単一機関による遡及的研究
Naoto Okada1, Hikaru Kimura1, Masakazu Ozaki1
1Pharmacy Department, Yamaguchi University Hospital, Yamaguchi 755-8505, Japan.
Biological & pharmaceutical bulletin
|February 18, 2026
まとめ
5-アミノレブリン酸 (5-ALA) による膀がんの光動力学的診断後の持続的な低血圧は,手術前の低血球濃度と関連しています. この発見は,手術後の長期低血圧のリスクが高い患者を特定するのに役立ちます.
科学分野:
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
- 医療診断 医療診断
背景:
- 5-アミノレブリン酸 (5-ALA) は,膀がんの光ダイナミック診断 (PDD) に利用され,腫瘍の可視化のために光を誘発します.
- 低血圧は,5-ALA PDDの既知の有害作用であり,以前の研究は投与直後のイベントに焦点を当てていました.
- 5-ALA投与の日を超えて持続する持続的な低血圧は,継続的な患者管理を必要とするが,その危険因子はよく定義されていない.
研究 の 目的:
- 膀がんPDDに対する5-ALA投与後の持続性低血圧に関連した危険因子を特定する.
- 術前臨床的特徴と術後の持続的な低血圧の発達との関係を調査する.
主な方法:
- 遡及的研究では,膀がんの5-ALA PDDを受けた263人の患者を分析した.
- 患者は,投与後1日の血圧に基づいて,持続性 (n=30) と非持続性 (n=153) の低血圧グループに分けられた.
- 多変数ロジスティック回帰と受容器操作特性 (ROC) 曲線分析を使用して,リスク要因を特定し,低血圧を予測しました.
主要な成果:
- 術前のヘモグロビン濃度は,持続性低血圧グループでは,持続性のないグループと比較して有意に低かった (p <0.05).
- 手術前低血球は,持続性低血圧 (OR,0.76;95%CI,0.60-0.97) の独立した危険因子として特定されました.
- ROC曲線解析により,継続的な低血圧を予測するために,手術前のヘモグロビンカットオフ値12.9g/dLを決定しました.
結論:
- 術前ヘモグロビンレベルは,膀がん患者における5-ALA PDD後の持続性低血圧の重要な独立リスク因子です.
- 12.9g/dL未満の術前ヘモグロビンレベルは,長時間低血圧を発症するリスクの増加を示唆する可能性があります.
- これらの発見は,手術前ヘモグロビン評価が,5-ALA誘発性低血圧のリスクのある患者を分層化し,手術後のケアを導くのに役立つことを示唆しています.
関連する概念動画
Alterations in Blood Pressure
2.3K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
2.3K
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
282
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282
Hypertension III: Clinical Manifestations and Diagnostic Studies
636
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
636
Factors Affecting Protein-Drug Binding: Patient-Related Factors
354
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
354
Factors Affecting Renal Clearance: Renal Impairment
509
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
509


